ins & outs

Bridgepoint news

Bridgepoint acquires leading drug

components group

Bridgepoint has bought PharmaZell, a top manufacturer of specialist ingredients for the pharmaceutical industry

PharmaZell is a global leader in the production of active pharmaceutical ingredients (APIs), which are used by drug companies around the world.

APIs act as key components in drugs and PharmaZell has developed a portfolio of more than 70 products, with a particular focus on the treatment of respiratory, inflammatory and liver disease.

Founded in Bavaria after the Second World War, the company has been making APIs for more than 70 years. Today, it operates four state-of-the-art sites in Germany, Italy and India, and has more than 900 employees worldwide.

 

The global market for small-molecule APIs is estimated at more than $70 billion and the outlook is highly encouraging, as demand is growing and large drug companies are increasingly turning to niche suppliers to manufacture key components.

 

Bridgepoint senior partner Carsten Kratz says: “PharmaZell represents an exciting opportunity to invest in a robust platform with an experienced management team and a high-quality customer base in the growing and non-cyclical pharma market.” n

French financial adviser gains support from Bridgepoint Development Capital

Cyrus is a leading financial advisory and asset management business in France, with more than 10,000 clients, including many high net worth individuals and entrepreneurs. The group manages more than €3.5 billion of assets and structures real estate investments for clients, too.

Bridgepoint Development Capital (BDC) has now acquired a minority stake in Cyrus, to provide support as it pursues a high-growth strategy. The French independent financial advisor market is worth €1.8 billion and is

highly fragmented, with more than 3,000 participants. Cyrus is well placed to act as a consolidator in the industry, as it is well regarded and has developed a leadership position in its sector.

In recent years, too, French independent advisers have taken market share from traditional banks and insurers n

BDC invests in fast-expanding Nordic dental group

Bridgepoint Development Capital (BDC) has acquired a majority stake in Oris Dental, a leading Norwegian dental care provider, with a nationwide portfolio of clinics and laboratories.

Established in 2016, the company has expanded fast and today operates 25 clinics and four laboratories across Norway. Headquartered in Trondheim Norway’s third-largest city, it has ambitious plans for

growth, both organically and through acquisition.

“We are very impressed by Oris Dental's progress to date. The company has built a

leading position in the Norwegian market, thanks to its focus on high-quality services and

a dentist-centric model. We look forward to partnering the team to develop the business

further,” says BDC partner Johan Dahlfors n

Life insurance broker wins capital investment

Bridgepoint Development Capital (BDC) is making a minority growth capital investment in Reassured, one of the UK’s biggest life insurance brokers.

Under the transaction, BDC will support Reassured as it expands in its field, developing new products and investing in technology to improve scalability and efficiency.

BDC managing partner Michael Black, says: “We are delighted to be partnering the team at Reassured. Supporting highly ambitious and driven founders and executives in high growth businesses is at the heart of what we do.”

Reassured founder and CEO Steve Marshall says: “We’ve been growing our business at an unprecedented rate over the past few years. Partnering Bridgepoint, with its substantial expertise in growing businesses, creates an opportunity to build and diversify our business even further.” n

© Bridgepoint 2020   |   About The Point magazine   |   Legal notice